August 2023

16 Aug Pembrolizumab plus Lenvatinib as First-line Therapy for Advanced Non-clear-cell Renal Cell Carcinoma (KEYNOTE-B61)

In the KEYNOTE-B61 phase 2, single-arm study, patients with previously untreated stage IV non-clear-cell renal cell carcinoma treated with pembrolizumab plus lenvatinib showed a confirmed objective response (49%; 95% CI 41-57), including confirmed complete response (6%) and partial response (44%). The most common Grade 3-4 treatment-related adverse events were hypertension (23%), proteinuria (4%), and stomatitis (4%). (Albiges L, et al. Lancet Oncol. August, 2023)

#oncologyresearch #clinicalresearch #clinicaldevelopment

12 Aug Erdafitinib in patients with advanced solid tumours with FGFR alterations

In single-arm, phase 2 RAGNAR study, treatment with erdafitinib (selective pan-FGFR tyrosine kinase inhibitor) showed clinical benefit in the tumour-agnostic setting in patients with advanced solid tumours with susceptible FGFR alterations who have exhausted other treatment options. An objective response was observed in 64 (30% [95% CI 24–36]) of 217 patients across 16 distinct tumour types. The most commonly occurring serious treatment-related adverse events (grade 3 or higher) were stomatitis (2%) and diarrhoea (1%). (Pant S, et al. Lancet Oncol. August 2023)